2025 Guidelines for the Evaluation and Management of Adults With Congenital Heart Disease
December 19, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Cantil
Synonyms :
Class :
Anticholinergic Agent and antispasmodics
Brand Name :
Cantil
Synonyms :
Class :
Anticholinergic Agent and antispasmodics
Dosage Forms & Strengths
Tablet- as bromide:
25 mg [DSC- discontinued product]
Safety and efficacy not established
Avoid use
it may increase the effect of anticholinergic agents
it may increase the effect of anticholinergic agents
it may increase the constipating effect of eluxadoline
it may increase the effect of anticholinergic agents
it may increase the anticholinergic effect of Revefenacin
it increases the effect of anticholinergic agents
they increase the anticholinergic effect of tiotropium
anticholinergic agents increase the efficacy of cimetropium
anticholinergic agents increase the effect of constipation of eluxadoline
it increases the effect of anticholinergic agents
it increases the effect of anticholinergic agents
anticholinergic agents increase the ulcer-producing effect of potassium chloride
it increases the effect of anticholinergic agents
it increases the effect of anticholinergic agents
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
May enhance the tachycardic effect
May enhance the tachycardic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
When mepenzolate is used together with profenamine, this leads to enhanced risk or seriousness of adverse events
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
anticholinergic agents decrease the efficacy of other ACE inhibitors
anticholinergic agents decrease the efficacy of other ACE inhibitors
anticholinergic agents decrease the efficacy of other ACE inhibitors
anticholinergic agents decrease the efficacy of other ACE inhibitors
anticholinergic agents decrease the efficacy of other ACE inhibitors
anticholinergic agents increase the effect of tachycardia of cannabinoid-containing products
anticholinergic agents increase the effect of tachycardia of cannabinoid-containing products
anticholinergic agents increase the toxicity of glucagon
anticholinergic agents decrease the efficacy of itopride
it increases the toxicity of anticholinergic agents
anticholinergic agents diminish the absorption of nitroglycerin
anticholinergic agents increase the toxicity of opioid agents
anticholinergic agents increase the toxicity of opioid agents
anticholinergic agents increase the toxicity of opioid agents
anticholinergic agents increase the toxicity of opioid agents
anticholinergic agents decrease the efficacy of secretin methacholine
Adverse drug reactions:
Frequency not defined
Palpitations
tachycardia
Confusion
Dizziness
Drowsiness
Headache
Insomnia
nervousness
Hypohidrosis
urticaria
Anaphylaxis
Weakness
Blurred vision
Cycloplegia
mydriasis
Pregnancy warnings:
Pregnancy Category: B
Breastfeeding warnings:
The release of the drug into the human breastmilk is unknown
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits
Category X: Drugs listed in this category outweigh risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: mepenzolate
Pronunciation: me PEN zoe late
Why do we use mepenzolate?
Mepenzolate is an anticholinergics agent which acts as a antispasmodic drug used to treat peptic ulcer
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
